Some nice points from the always excellent Brian Johnston at CLSA:
CBA likely faces higher operating costs, higher operational risk capital and reduced pricing power from AUSTRAC AML allegations, according to CLSA’s Brian Johnson.
And while quantitative signals favour a switch to CBA from WBC, it’s too early to buy given further retail selling of DRP scrip issuance and the very real likelihood of a rebasing of earnings under new management.